Eloxx pharmaceuticals, inc. (ELOX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Jun'17Dec'16Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10
Cash flows from operating activities:
Net loss

-50,874

-47,185

-21,214

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-5,796

-9,847

-8,267

-18,063

-9,225

-6,122

-5,066

-7,268

-13,383

Adjustments to reconcile net loss to net cash used in operating activities:
- stock right

-

-

-

651

-

254

12

0

-

-

-

-

- warrant liability

-

-

-

249

-

1,993

3

0

-

-

-

-

- derivative liability

-

-

-

-1,175

-

-

-

-

-

-

-

-

Noncash charge for modification of warrant terms

-

-

-

285

-

-

-

-

-

-

-

-

Noncash charge for change in warrant terms

-

-

-

-

-

-

-

-

-

-

115

-

Issuance of common stock and warrants for interest

-

-

-

-

-

-

-

-

-

-

0

552

Noncash charge for common stock anti-dilution issuance

-

-

-

1,417

-

0

0

-

-

-

0

53

Noncash charge for accretion of debt discount

-

-

-

241

-

-

-

-

-

-

-

-

Gain on sale of patents

-

-

-

149

-

0

0

-

-

-

-

-

Noncash capital contribution

-

-

-

-

-

-

-

-

-

-

0

-

Noncash conversion of accrued expenses into equity

-

-

-

-

-

-

-

-

-

-

0

-

Noncash income related to change in fair value of warrant liability

-

-

-

-

-

-

-

-

371

472

609

2,516

Stock-based compensation

11,336

13,370

101

80

78

156

480

1,297

724

766

750

386

Depreciation

87

216

39

-

8

-

-

-

-

-

-

-

Loss (gain) on sales and disposals of property and equipment

2

-12

-

-

-

-

-

-

-

-

-

-

Amortization of operating lease right-of-use asset

472

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

44

-

93

177

349

293

258

143

126

Impairment of goodwill

-

-

-

-

-

-

-

-

64

321

1,588

-

Loss on disposal of assets

-

-

-

0

-

0

-8

0

-

-

-

-

Impairment of goodwill

-

-

-

0

-

5,780

8,121

0

-

-

-

-

Write-off of intangibles

-

-

-

2,600

-

1,700

2,290

1,680

-

-

-

-

Deferred Tax

-

-

-

-1,040

-

-680

0

-

-

-

-

-

Write-off of prepaid research supplies

-

-

-

0

-

0

669

0

-

-

-

-

Deferred rent

-

-

-

22

-

62

-85

0

-

-

8

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

7

Amortization of debt discount

535

-

-

-

-

-

-

-

-

-

0

9,448

Amortization of premiums and discounts on investments

301

-

-

-

-

-

-

-

-

-

-

-

Amortization and revaluation of discount in respect to convertible loan

-

-

668

-

-

-

-

-

-

-

-

-

Provision related to the Technion exit fee

-

-

3,416

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Amortization of deferred financing costs

-

-

-

-

-

-

-

-

-

-

0

632

Loss on settlement of warrant liabilities

-

-

-

-

-

-

-

0

-1,724

0

0

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

0

-361

Prepaid expenses and other current assets

-83

1,080

-709

79

482

-223

-48

-868

370

102

141

143

Other assets

-

41

-

-

-

-

-

-

-

-

-

-

Security deposit

-

-

-

-40

-

0

45

0

0

-7

5

-

Accounts payable

1,124

-780

-583

101

1,250

-141

-669

-145

42

34

2

-419

Accrued expenses

-1,300

3,999

929

76

149

-155

-507

305

112

-132

41

165

Operating lease liabilities

-472

-

-

-

-

-

-

-

-

-

-

-

Taxes payable

-79

122

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-39,391

-31,367

-15,935

-

-8,844

-

-

-

-3,902

-4,386

-5,391

-4,743

Cash flows from investing activities:
Purchases of marketable securities

67,214

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

33,750

-

-

-

-

-

-

-

-

-

-

-

Investment in restricted bank deposit

-

-

-

-

14

-

-

-

-

-

-

-

Deferred revenue

-

-

-

0

-

-75

75

0

-

-

-

-

Net cash used in operating activities

-

-

-

-1,925

-

-3,676

-7,344

-4,868

-

-

-

-

Proceeds from sale of patents

-

-

-

50

-

0

0

-

-

-

-

-

Capitalized patent costs

-

-

-

0

-

0

136

624

527

446

684

807

Redemption of investments, net

-

-

-

-

-

-

-

-

-

-

-

-1,050

Purchase of property and equipment

40

235

237

2

36

0

122

3

1

4

2

1

Proceeds from sales of property and equipment

2

6

-

-

-

-

-

-

-

-

-

-

Cash paid for long-term deposits

22

88

-

-

-

-

-

-

-

-

-

-

Cash received upon the Reverse Merger

-

-

123

-

-

-

-

1,274

0

0

-

-

Net cash provided by investing activities

-

-

-

47

-

0

-259

646

-

-

-

-

Proceeds (repayments) from line of credit

-

-

-

-

-

-

-

2,187

-

-

-

-

Net cash provided by (used in) investing activities

-33,524

-317

-114

-

-50

-

-

-

-529

-450

-686

240

Cash flows from financing activities:
Proceeds from debt financing obligation

15,000

-

-

-

-

-

-

-

-

-

-

-

Payment of debt issuance costs

276

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants into Series A preferred stock

-

-

-

-

350

-

-

-

-

-

-

-

Proceeds from exercises of stock options

169

446

17

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock under at-the-market sales agreement

-

-

17,006

-

-

-

-

-

-

-

-

-

Payment for settlement of taxes upon vesting of restricted stock units

1,378

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of Series B-1 preferred stock and warrants to purchase Series B-1 preferred stock, net of issuance costs

-

-

-

-

9,386

-

-

-

-

-

-

-

Proceeds from grant

-

-

-

-

-

-

-

-

-

-

0

-

Repayment of line of credit

-

-

-

-

-

-

-

-

-12

0

4

-

Proceeds from draw-down on line of credit

-

-

-

-

-

-

-

-

-

-

-

2,194

Proceeds from issuance of preferred stock and warrants, net

-

-

-

-

-

-

-

-

-

-

0

10,754

Redemption of convertible notes and warrants

-

-

-

-

-

-

-

-

-

-

0

2,160

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

0

-

Proceeds from convertible loan and related financial derivative into Series C preferred stock

-

-

2,500

1,100

-

0

0

-

-

-

-

-

Proceeds from advances from collaboration partners

403

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock and warrants, net and exercise of warrants and options

-

-

-

0

-

1,152

4,827

10,917

4,044

3,227

1,657

1,359

Net cash provided by financing activities

-

-

-

1,100

-

1,152

4,827

8,730

-

-

-

-

Net cash (used in) provided by financing activities

46,800

56,184

37,950

-

9,736

-

-

-

4,032

3,227

1,661

12,147

Increase (decrease) in cash, cash equivalents and restricted cash

-26,115

24,500

21,901

-

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents and restricted cash to condensed consolidated balance sheets:
Decrease in cash and cash equivalents

-

-

-

-777

842

-2,523

-2,776

4,509

-399

-1,608

-4,416

7,645

Dividends accrued on preferred stock

-

-

-

-

-

-

-

14

-

-

-

-

Reclass warrant liability to equity

-

-

-

56

-

0

0

-

-

-

-

-

Deemed dividend - preferred stock

-

-

-

354

-

0

0

-

-

-

-

-

Supplemental disclosure of cash flow activities:
Cash paid for interest

986

-

-

-

-

-

-

-

-

-

-

-

Cash paid for income taxes, net of refunds received

36

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash financing activities:
Non-cash acquisition of treasury stock

-

1,129

-

-

-

-

-

-

-

-

-

-

Non-cash issuance of common stock upon exercise of warrants

179

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants issued in connection with long-term debt

421

-

-

-

-

-

-

-

-

-

-

-

Remeasurement of operating leases

176

-

-

-

-

-

-

-

-

-

-

-

Conversion of convertible loan into Series C preferred stock

-

-

3,168

268

-

0

-

-

-

-

-

-

Conversion of preferred stock into common stock

-

-

-

17

-

6

0

0

-

-

-

-

Allocation of equity proceeds to warrants

-

-

-

0

-

559

1,742

0

-

-

-

-

Allocation of equity proceeds to stock rights

-

-

-

0

-

142

775

0

-

-

-

-

Allocation of preferred stock proceeds to beneficial conversion feature

-

-

-

0

-

135

790

0

-

-

-

-

Allocation of convertible note proceeds to derivative liability

-

-

-

1,101

-

0

0

-

-

-

-

-

Issuance of common stock for interest payments on convertible notes

-

-

-

42

-

40

56

-

-

-

-

-

Issuance expenses of Series C Preferred Shares

-

-

-

0

-

0

0

118

-

-

-

-

Proceeds receivable from equity sales agreement

-

255

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

0

-

0

0

85

122

134

-

-

Fair value of equity interests issued:

-

-

-

-

-

-

-

20,709

-

-

-

-

Issuance of common stock, warrants and options in connection with the acquisition of Fabrus, Inc.

-

-

-

-

-

-

-

-

0

0

-

-

Accounts Receivable

-

-

-

-

-

-

-

43

0

0

-

-

Prepaid Expenses

-

-

-

-

-

-

-

19

0

0

-

-

Prepaid Expenses

-

-

-

-

-

-

-

-

0

0

-

-

Equipment

-

-

-

-

-

-

-

234

0

0

-

-

Acquired Research and Development

-

-

-

-

-

-

-

9,800

0

0

-

-

Acquired Research and Development

-

-

-

-

-

-

-

-

0

0

-

-

Goodwill

-

-

-

-

-

-

-

13,902

0

0

-

-

Total assets acquired

-

-

-

-

-

-

-

23,999

-

-

-

-

Accounts Payable

-

-

-

10

-

9

6

409

0

0

-

-

Accrued Payroll

-

-

-

-

-

-

-

74

0

0

-

-

Accrued Expenses

-

-

-

-

-

-

-

161

0

0

-

-

Deferred Tax Liability

-

-

-

-

-

-

-

3,920

-

-

-

-

Accrued Payroll

-

-

-

-

-

-

-

-

0

0

-

-

Accrued Expenses

-

-

-

-

-

-

-

-

0

0

-

-

Total Liabilities accquired

-

-

-

-

-

-

-

4,565

-

-

-

-

Cash acquired in acquisition of Fabrus, Inc.

-

-

-

-

-

-

-

1,274

0

0

-

-

Equity Sales Agreement [Member]
Proceeds from issuance of common stock

710

2,165

-

-

-

-

-

-

-

-

-

-

Underwritten Public Offering [Member]
Proceeds from issuance of common stock

32,172

53,573

-

-

-

-

-

-

-

-

-

-

Series C Preferred Stock [Member]
Proceeds from issuance of preferred stock

-

-

18,427

-

-

-

-

-

-

-

-

-

Issuance expenses of Series C Preferred Shares

-

-

242

-

-

-

-

-

-

-

-

-